News >

FDA Grants Fast Track Designation to ARV-110 for mCRPC

Gina Columbus @ginacolumbusonc
Published: Wednesday, May 29, 2019

John Houston, PhD

John Houston, PhD

The FDA has granted a fast track designation to ARV-110, a PROTAC® protein degrader, for use as a treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have disease progression following ≥2 systemic therapies.

Arvinas Receives Fast Track Designation for its Targeted Protein Degrader ARV-110 as a Treatment for Men with Metastatic Castration-Resistant Prostate Cancer. Arvinas, Inc. Published May 29, 2019. Accessed May 29, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication